Last Update Time:
04-Mar-2025 16:00:00
ISIN:
INE232I01014
Sector:
Healthcare
Symbol:
SPARC
Sun Pharma Advanced Research Company Limited
₹122.88
₹10.87
(9.70%)
▲
Prev. Close
₹112.01
Open
₹111.96
Close
₹127.04
Range
₹116.74 - ₹129.02
High
₹132.70
Low
₹111.04
Ind. Close
₹0.00
VWAP
₹123.57
The current stock price of Sun Pharma Advanced Research Company Limited is ₹122.88, with a target price range between ₹116.74 and ₹129.02. The stock has experienced a price change of ₹10.87 (9.70%), reflecting recent market volatility.
Today's opening price was ₹111.96, while the previous close stood at ₹112.01.
The market trend suggests an uptrend, making it an attractive investment opportunity for traders seeking short-term gains.
For real-time stock market updates, live share prices, and stock analysis, stay tuned. Understanding key stock metrics like VWAP, high-low range, and market momentum can help traders make informed investment decisions.
Sun Pharma Advanced Research Company Limited Price Chart
Sun Pharma Advanced Research Company Limited Pre Open Market Overview: 04-Mar-2025
Key Metrics:
- IEP (Indicative Equilibrium Price): 111.96
- Previous Close Price: 112.01
- Change: -0.05%
- Total Traded Volume: 2,206
- Total Buy Quantity: 20,931
- Total Sell Quantity: 28,837
| Price | Buy Qty | Sell Qty |
|---|---|---|
| 110.20 | 5,000.00 | 0.00 |
| 110.70 | 160.00 | 0.00 |
| 110.80 | 50.00 | 0.00 |
| 111.00 | 220.00 | 0.00 |
| 111.35 | 500.00 | 0.00 |
| 111.96 | 0.00 | 424.00 |
| 112.00 | 0.00 | 150.00 |
| 112.01 | 0.00 | 280.00 |
| 112.50 | 0.00 | 100.00 |
| 112.70 | 0.00 | 500.00 |
ATO Data:
- Buy Quantity (ATO): 0
- Sell Quantity (ATO): 0
Order Book
| Bid | Qty | Ask | Qty |
|---|---|---|---|
| 0.00 | 0 | 0.00 | 0 |
| 0.00 | 0 | 0.00 | 0 |
| 0.00 | 0 | 0.00 | 0 |
| 0.00 | 0 | 0.00 | 0 |
| 0.00 | 0 | 0.00 | 0 |
Total Buy Quantity: 20931
Total Sell Quantity: 28837
Shareholding Patterns of Sun Pharma Advanced Research Company Limited
Key Trade Statistics of Sun Pharma Advanced Research Company Limited
| Trade Information | Details |
|---|---|
| Traded Volume (Lakhs) | 51.98 |
| Traded Value (₹ Cr.) | 64.23 |
| Total Market Cap (₹ Cr.) | 3,987.45 |
| Free Float Market Cap (₹ Cr.) | 1,220.03 |
| Impact cost | 0.09 |
| Quantity Traded | 5,197,809.00 |
| Deliverable Quantity | 1,024,052.00 |
| % of Quantity to Traded | 19.7 |
| Security VaR | 18.44 |
| Index VaR | N/A |
| VaR Margin | 18.44 |
| Extreme Loss Rate | 3.5 |
| Adhoc Margin | N/A |
| Applicable Margin Rate | 21.94 |
| Face Value | 1 |
Key Price Statistics of Sun Pharma Advanced Research Company Limited
The 52-week high for Sun Pharma Advanced Research Company Limited was ₹472.80, recorded on 09-Apr-2024. On the other hand, the 52-week low stands at ₹109.30, with the lowest value recorded on 03-Mar-2025.
The upper band for trading is ₹134.41, and the lower band is ₹89.60. The price band is 20%.
The stock's daily volatility stands at 2.82, while the annualized volatility is 53.88. The tick size for trading is ₹0.01.
| Price Information | Details |
|---|---|
| 52 Week High (09-Apr-2024) | 472.80 |
| 52 Week Low (03-Mar-2025) | 109.30 |
| Upper Band | 134.41 |
| Lower Band | 89.60 |
| Price Band (%) | 20 |
| Daily Volatility | 2.82 |
| Annualised Volatility | 53.88 |
| Tick Size | 0.01 |
Key Securities Statistics of Sun Pharma Advanced Research Company Limited
| Securities Information | Details |
|---|---|
| Status | Listed |
| Trading Status | Active |
| Date of Listing | 18-Jul-2007 |
| Adjusted P/E | 0 |
| Symbol P/E | 0 |
| Index | NIFTY 500 |
| Macro-Economic Sector | Healthcare |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Basic Industry | Pharmaceuticals |
Security Status of Sun Pharma Advanced Research Company Limited
| Title | Details |
|---|---|
| Board Status | Main |
| Trading Segment | Normal Market |
| Session No. | - |
| Class of Shares | Equity |
| SDD Compliance | - |
| Name of Compliance Officer | - |
Announcements of Sun Pharma Advanced Research Company Limited
| Subject | Date |
|---|---|
| Copy of Newspaper Publication | 12-Feb-2025 |
| Integrated Filing- Financial | 10-Feb-2025 |
| Outcome of Board Meeting | 10-Feb-2025 |
| Financial Result Updates | 10-Feb-2025 |
| Board Meeting Intimation | 31-Jan-2025 |
| Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent | 17-Jan-2025 |
| Change in Management | 17-Jan-2025 |
| Certificate under SEBI (Depositories and Participants) Regulations, 2018 | 10-Jan-2025 |
Corporate Actions of Sun Pharma Advanced Research Company Limited
| Face Value | Purpose | Ex-Date |
|---|---|---|
| 1 | Annual General Meeting | 21-Sep-2021 |
| 1 | Annual General Meeting | 22-Sep-2020 |
| 1 | Annual General Meeting | 18-Jul-2019 |
| 1 | Annual General Meeting | 19-Jul-2018 |
| 1 | Annual General Meeting | 27-Jul-2017 |
| 1 | Extraordinary General Meeting | 25-May-2017 |
| 1 | Annual General Meeting | 21-Jul-2016 |
| 1 | Rights 5: 116 At Premium Rs 244/- Per Share | 16-Mar-2016 |
| 1 | Annual General Meeting | 23-Jul-2015 |
| 1 | Annual General Meeting | 24-Jul-2014 |
| 1 | Annual General Meeting | 24-Jul-2013 |
| 1 | Rights 1: 7@ Premium Rs 66 Per Share | 23-Aug-2012 |
| 1 | Annual General Meeting | 28-Jul-2011 |
| 1 | Annual General Meeting | 16-Jul-2010 |
| 1 | Annual General Meeting | 21-Aug-2009 |
| 1 | Annual General Meeting | 25-Aug-2008 |
| 1 | Agm | 28-Aug-2007 |
Board Meetings of Sun Pharma Advanced Research Company Limited
Financial Results of Sun Pharma Advanced Research Company Limited
Company Directory of Sun Pharma Advanced Research Company Limited
| Web Address | Office | Address | City |
|---|---|---|---|
| https://www.sparc.life/ | Head Office/ Corporate Office | 17B Mahal Industrial Estate Mahakali Caves Road Andheri (East) | MUMBAI |
| https://www.sparc.life/ | Registered Office | Plot No. 5&6/1, Savli G.I.D.C. Estate, Savli - Vadodara Highway, Manjusar | VADODARA |
| https://www.sparc.life/ | Transfer Agent | Link Intime India Private Limited C-13, Pannalal Silk Mills Compound, LBS Marg, Bhandup(W), | MUMBAI |
Insider Trading of Sun Pharma Advanced Research Company Limited
| Reg. Clause | Acq./Disp. | Sec. Value | Txn Type |
|---|---|---|---|
| 7(2) | Raksha S Valia | 419760000 | Pledge |
| 7(2) | SUDHIR V VALIA | 343440000 | Pledge |
| 7(2) | DILIP SHANTILAL SHANGHVI | 3375000017 | Buy |
| 7(2) | DILIP SHANTILAL SHANGHVI | 0 | Sell |
| 7(2) | Raksha S Valia | 406220000 | Pledge |
| 7(2) | Raksha S Valia | 772156000 | Pledge |
| 7(2) | Raksha S Valia | 229400000 | Pledge |
| 7(2) | Raksha S Valia | 74906000 | Pledge |
| 7(2) | Raksha S Valia | 177828000 | Pledge |
| 7(2) | Raksha S Valia | 281905000 | Pledge |
| 7(2) | DILIP SHANTILAL SHANGHVI | 1124999961 | Buy |
| 7(2) | DILIP SHANTILAL SHANGHVI | 0 | Sell |
| 7(2) | DILIP SHANTILAL SHANGHVI | 1499999993 | Buy |
| 7(2) | Raksha S Valia | 143480000 | Pledge |
| 7(2) | Raksha S Valia | 198882000 | Pledge |
| 7(2) | Raksha S Valia | 162008000 | Pledge |
| 7(2) | Raksha S Valia | 252054000 | Pledge |
| 7(2) | Raksha S Valia | 617780000 | Pledge Revoke |
| 7(2) | Raksha S Valia | 494190000 | Pledge |
| 7(2) | SUDHIR V VALIA | 214880000 | Pledge Revoke |
Annual Reports of Sun Pharma Advanced Research Company Limited
Investor Complaints of Sun Pharma Advanced Research Company Limited
Event Calendar of Sun Pharma Advanced Research Company Limited
| Purpose | Details |
|---|---|
| Rights Issue | To consider in principle, the issue of equity shares of Re.1 each of the Company by way of rights issue for raising the funds for the Company. Further the Company has informed the Exchange that as per the agenda of the Committee Meeting, however the Committee shall not decide at the said meeting about the ratio of rights share entitlements, the issue price and the record date for fixing the rights entitlement of shareholders & which shall be decided in due course . |
| Financial Results | Interalia, to consider and take on record the Financial Results of the Company for the second quarter/ half year ended September 30, 2011. |
| Results | Interalia, to consider and approve the Audited Financial Results of the Company for the year ended March 31, 2013. |
| Results | Interalia, to consider and take on record the Un-audited Financial Results of the Company for the first quarter ended June 30, 2013. |
| Results | Interalia, to consider and take on record the Un-audited Financial Results of the Company for the second quarter /half year ended September 30, 2013. |
| Results | Interalia, to consider and take on record the Un-audited Financial Results of the Company for the third quarter ended December 31, 2013. |
| Results | Interalia, to consider and approve the Audited Financial Results of the Company for the year ended March 31, 2014. |
| Results | Interalia, to consider and take on record the Un-audited Financial Results of the Company for the first quarter ended June 30, 2014. Further that window closure for Trading by Designated persons as per Insider Trading Rules of the Company will be from July 22, 2014 to August 04, 2014 (both days inclusive). |
| Results | Interalia to consider and take on record the Unaudited Financial Results of the Company for the second quarter / half year ended September 30, 2014. |
| Results | Interalia, to consider and take on record the Un-audited Financial Results of the Company for the third quarter ended December 31, 2014. |
| Results | interalia, to consider and take on record the Audited Financial Results of the Company for the year ended March 31, 2015. |
| Rights Issue | Inter alia, to consider in principle, the issue of equity shares of Re. 1 each of the Company by way of rights issue for raising the funds for the Company. Further, The Company has inform that as per the agenda of the Board Meeting, at present the Board shall not decide at the said meeting about the ratio of rights share entitlements, the issue price and the record date for fixing the rights entitlement of shareholders & which shall be decided in due course and accordingly the exchanges shall be informed in due course. |
| Results | To consider, inter alia, the un-audited financial results of the Company for the quarter ended June 30, 2015. |
| Results | to consider, inter alia, the un-audited financial results of the Company for the quarter and half year ended September 30, 2015. |
| Results | to consider, inter alia, the un-audited financial results of the Company for the quarter and nine months ended 31st December 2015. |
| Others | inter alia, to fix the Issue Price, Issue Size, Rights Entitlement Ratio, Fractional Entitlemcnt and Record Date/ Book Closure Dates for determining eligibility of the shareholders to whom the equity shares are to be issued under the proposed Rights Issue of the Company. |
| Results | to consider, inter alia, to consider and take on record, the audited financial results of the Company for the year ended March 31, 2016. |
| Results | inter alia, to consider and take on record, the un-audited financial results of the Company for the quarter ended June 30, 2016. |
| Results | Inter alia, to consider and take on record, the un-audited financial results of the Company for the quarter and half year ended September 30, 2016. Further, kindly note that the trading window for trading by designated persons shall be closed from October 19, 2016 to November 02, 2016 (both days inclusive) in view of the above. |
| Results | inter alia, to consider and take on record, the un-audited financial results of the Company for the quarter and nine months ended December 31, 2017. Further, pursuant to the Company s Code of Internal Procedures and Code of Conduct for Prevention of Insider Trading, the trading window for trading by designated persons shall be closed from January 17,2017 to January 31, 2017 (both days inclusive) in view of the above. |
| Preferential issue | inter alia ,also consider a proposal for raising of additional funds by way of issue of equity shares / warrants convertible into equity shares of the Company on preferential basis to certain promoter/ non-promoter entities, subject to the receipt of necessary approvals including approval of the shareholders at an Extra ordinary general meeting, and to determine the issue price. |
| Results | Inter alia, to consider and take on record, the audited financial results of the Company for the quarter and twelve months ended March 31, 2017. |
| Results | Inter alia, to consider and take on record, the unaudited financial results of the Company for the quarter ended June 30, 2017. |
| Results | inter alia, to consider and take on record, the unaudited financial results of the Company for the quarter and half year ended September 30, 2017. |
| Results | inter alia, to consider and take on record, the unaudited financial results of the Company for the quarter and nine months ended December 31, 2017. |
| Financial Results | To consider and approve the financial results for the period ended March 31, 2018 |
| Financial Results/Other business matters | To consider and approve the financial results for the period ended Jun 30, 2018 and other business matters |
| Financial Results | To consider and approve the financial results for the period ended September 30, 2018 |
| Financial Results | To consider and approve the financial results for the period ended December 31, 2018 |
| Financial Results | To consider and approve the audited financial results for the period ended March 31, 2019 |
| Financial Results | To consider and approve the unaudited financial results for the first quarter ended Jun 30, 2019 |
| Financial Results | To consider and take on record the unaudited financial results of the Company for the quarter and six months ended September 30, 2019 |
| Financial Results | To consider and approve the unaudited financial results for the period ended December 31, 2019 |
| Financial Results | To consider and approve the financial results for the period ended March 31, 2020 |
| Financial Results | To consider and approve the unaudited financial results for the quarter ended Jun 30, 2020 |
| Financial Results | To consider and approve the financial results for the period ended September 30, 2020 |
| Financial Results | Notice of Board Meeting to consider and approve the unaudited financial results for the quarter period ended December 31, 2020 |
| Fund Raising | To consider Fund Raising |
| Financial Results | Notice of Board Meeting for consideration of audited results of the Company for the quarter and financial year ended 31st March 2021 |
| Financial Results | Pursuant to Regulation 29(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that a meeting of the Board of Directors of the Company will be held on Monday, July 26, 2021, to inter alia consider and approve, the unaudited financial results of the Company for the quarter ended June 30, 2021. |
| Fund Raising | To consider Fund Raising |
| Financial Results | To consider and approve the unaudited financial results for the period ended September 30, 2021 |
| Financial Results | To consider and approve the financial results for the quarter and nine months ended December 31, 2021 |
| Financial results | Sun Pharma Advanced Research Company Limited has informed the Exchange about Board Meeting to be held on 17-May-2022 to consider Audited financial Results for the quarter and financial year ended March 31, 2022 |
| Financial results | Sun Pharma Advanced Research Company Limited has informed the Exchange about Board Meeting to be held on 07-Nov-2022 to consider Unaudited financial Results for the period ended September 2022 |
| Financial Results | To consider and approve the financial results for the quarter and year ended March 31, 2023 |
| Fund Raising | To consider Fund Raising |
| Financial Results | To consider and approve the financial results for the period ended Jun 30, 2023 |
| Financial Results | To consider and approve the financial results for the period ended September 30, 2023 |
| Financial Results | To consider and approve the financial results for the period ended December 31, 2023 |
| Financial Results/Fund Raising | To consider and approve the financial results for the period ended March 31, 2024 and Fund Raising |
| Financial Results | To consider and approve the financial results for the period ended Jun 30, 2024 |
| Financial Results | To consider and approve the financial results for the period ended September 30, 2024 |
| Financial Results | To consider and approve the financial results for the period ended December 31, 2024 |
Share Transfers of Sun Pharma Advanced Research Company Limited
Voting Results of Sun Pharma Advanced Research Company Limited
| Date of Mtg. | Mtg. Type | Resolution |
|---|---|---|
| 12-AUG-2024 | AGM | For adoption of audited standalone financial statements of the Company for the financial year ended March 31, 2024 and the reports of the Board of Directors and Auditors thereon. |
| 12-AUG-2024 | AGM | For raising of funds through equity shares, convertible warrants, preference shares/ bonds /debentures /any other instruments whether convertible into equity shares or not, American Depository Receipts (￢ﾀﾜADRs￢ﾀﾝ), Global Depository Receipts (￢ﾀﾜGDRs￢ﾀﾝ), Foreign Currency Convertible Bonds (￢ﾀﾜFCCBs￢ﾀﾝ), etc. |
| 12-AUG-2024 | AGM | For appointment of Ms. Vidhi Dilip Shanghvi as a Non- Executive, Non-Independent Director of the Company. |
| 12-AUG-2024 | AGM | For re-appointment of Dr. Robert J. Spiegel (DIN: 08739625) as an Independent Director of the Company for a second term of five years. |
| 12-AUG-2024 | AGM | For retirement of Mr. Sudhir V. Valia (DIN: 00005561), Director liable to retire by rotation, who does not seek re-election. |
| 12-AUG-2024 | AGM | For adoption of the audited consolidated financial statements of the Company for the financial year ended March 31, 2024 and the report of the Auditors thereon. |
| 07-AUG-2023 | AGM | To receive, consider and adopt the audited financial statements of the Company for the financial year ended March 31, 2023 and the reports of the Board of Directors and Auditors thereon |
| 07-AUG-2023 | AGM | To approve raising of funds through equity shares, convertible warrants, preference shares/ bonds /debentures / any other instruments whether convertible into equity or not, American Depository Receipts (￢ﾀﾜADRs￢ﾀﾝ), Global Depository Receipts (￢ﾀﾜGDRs￢ﾀﾝ), Foreign Currency Convertible Bonds (￢ﾀﾜFCCBs￢ﾀﾝ), etc. |
| 07-AUG-2023 | AGM | To increase the limits applicable for making investments / extending loans and giving guarantees or providing securities in terms of Section 186 of the Companies Act, 2013 |
| 07-AUG-2023 | AGM | To approve the maximum remuneration of Mr. Anil Raghavan, Manager and Whole-time Key Managerial Personnel of the Company, designated as Chief Executive Officer (CEO), for further period of two years i.e. from May 25, 2024 to May 24, 2026 |
| 07-AUG-2023 | AGM | To re-appoint Dr. Rajamannar Thennati (DIN: 01415412), who retires by rotation and being eligible, has offered himself for re-appointment as a Director |
| 22-SEP-2022 | AGM | To receive, consider and adopt the audited financial statements of the Company for the financial year ended March 31, 2022 and the reports of the Board of Directors and Auditors thereon. |
| 22-SEP-2022 | AGM | To approve raising of the funds through equity shares, convertible warrants, preference shares/ bonds /debentures / any other instruments whether convertible into equity or not, American Depository Receipts (￢ﾀﾜADRs￢ﾀﾝ), Global Depository Receipts (￢ﾀﾜGDRs￢ﾀﾝ), Foreign Currency Convertible Bonds (￢ﾀﾜFCCBs￢ﾀﾝ), etc. |
| 22-SEP-2022 | AGM | To approve continuation of transactions with Sun Pharmaceutical Industries Inc., USA under Master Support Services Agreement. |
| 22-SEP-2022 | AGM | To approve continuation of transactions with Sun Pharmaceutical Industries Inc., USA under Shared Services Agreement. |
| 22-SEP-2022 | AGM | To approve revision in terms of Line of Credit availed from Shanghvi Finance Private Limited |
| 22-SEP-2022 | AGM | To re-appoint S R B C & Co. LLP, Chartered Accountants as the Statutory Auditors of the Company. |
| 22-SEP-2022 | AGM | To appoint Mr. Dilip S. Shanghvi (DIN: 00005588), who retires by rotation and being eligible, has offered himself for reappointment. |
| 29-SEP-2021 | AGM | To receive, consider and adopt the audited financial statements of the Company for the financial year ended March 31, 2021 and the reports of the Board of Directors and Auditors thereon. |
| 29-SEP-2021 | AGM | To appoint Mr. Sudhir V. Valia (DIN: 00005561), who retires by rotation and being eligible, has offered himself for reappointment as a Director. |
FAQs on Sun Pharma Advanced Research Company Limited
Disclaimer: The information provided here is for informational purposes only and should not be considered financial advice. Please do your own research and consult with a financial professional before making any investment decisions.